Recent Updates
Recently added Catalysts
KURA Positive Sentiment Score: 65/100

Kura Oncology to Report First Quarter 2023 Financial Results

Wednesday, May 3, 2023 2 min read
Key Takeaway: Kura Oncology announced it will report its first quarter 2023 financial results on May 10, 2023, after market close. A webcast and conference call will follow to discuss the results and provide updates on the company's operations. The company is actively involved in clinical trials for its drug candidates, including ziftomenib and tipifarnib, targeting specific cancer types.

Market Sentiment Analysis

POSITIVE FACTORS

  • Kura Oncology is focusing on precision medicines for cancer treatment.
  • The company is advancing multiple drug candidates in clinical trials.
  • Ziftomenib targets a specific cancer pathway and addresses high unmet need.

Full Press Release Details

SAN DIEGO, May 03, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2023 financial results after the close of U.S. financial markets on Wednesday, May 10, 2023. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing (888) 886-7786 for domestic callers and (416) 764-8658 for international callers. A live webcast and archived replay of the event will be available here or online from the investor relations section of the company website at www.kuraoncology.com.
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia (AML) patients with high unmet need. The Company is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) of ziftomenib in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors. For additional information, please visit Kura’s website at www.kuraoncology.com.
Senior Vice President, Investor Relations &
Corporate Communications
pete@kuraoncology.com
Alexandra Weingarten
Senior Manager, Corporate Communications
alexandra@kuraoncology.com

Tags

farnesyl transferase inhibitor

Frequently Asked Questions

When will Kura Oncology report its Q1 2023 financial results?

Kura Oncology will report its Q1 2023 financial results on May 10, 2023.

How can I access Kura's financial results call?

You can access the call by dialing (888) 886-7786 domestically or (416) 764-8658 internationally.

What is ziftomenib used for?

Ziftomenib targets the menin-KMT2A interaction for treating acute myeloid leukemia.

What trials is Kura currently conducting?

Kura is conducting Phase 1 and 2 trials for ziftomenib and tipifarnib in various cancers.

What does Kura Oncology focus on?

Kura Oncology focuses on precision medicines for cancer treatment.

Tags: KURA Viatris Investor Conferences Healthcare cancer treatment clinical trials ziftomenib tipifarnib
Last updated: May 3, 2023